Platforms for Personalized Polytherapeutics Discovery in COVID-19

Christopher Hopkins; Chidinma Onweni; Victoria Zambito; De Lisa Fairweather; Kathryn McCormick; Hideki Ebihara; Tom Caulfield; Yu Shrike Zhang; W. David Freeman

doi:10.1016/j.jmb.2021.166945

Platforms for Personalized Polytherapeutics Discovery in COVID-19

Christopher Hopkins, Chidinma Onweni, Victoria Zambito, De Lisa Fairweather, Kathryn McCormick, Hideki Ebihara, Tom Caulfield, Yu Shrike Zhang, W. David Freeman

Research output: Contribution to journal › Review article › peer-review

Abstract

The COVID-19 pandemic entered its third and most intense to date wave of infections in November 2020. This perspective article describes how combination therapies (polytherapeutics) are a needed focus for helping battle the severity of complications from SARS-CoV-2 infection. It outlines the types of systems that are needed for fast and efficient combinatorial assessment of therapeutic candidates. Proposed are micro-physiological systems using human iPSC as a format for tissue-specific modeling of infection, the use of gene-humanized zebrafish and C. elegans for combinatorial drug screens due to the animals being addressable in liquid multi-well formats, and the use of engineered pseudo-typing systems to safely model infection in the transgenic animals and engineered tissue systems.

Original language	English (US)
Article number	166945
Journal	Journal of Molecular Biology
Volume	433
Issue number	10
DOIs	https://doi.org/10.1016/j.jmb.2021.166945
State	Published - May 14 2021

Keywords

ACE2
COVID-19
SARS-CoV
antiviral
combination therapy

ASJC Scopus subject areas

Biophysics
Structural Biology
Molecular Biology

Access to Document

10.1016/j.jmb.2021.166945

Cite this

@article{4741efa566ca4b1ba2f78d554c4c0884,

title = "Platforms for Personalized Polytherapeutics Discovery in COVID-19",

abstract = "The COVID-19 pandemic entered its third and most intense to date wave of infections in November 2020. This perspective article describes how combination therapies (polytherapeutics) are a needed focus for helping battle the severity of complications from SARS-CoV-2 infection. It outlines the types of systems that are needed for fast and efficient combinatorial assessment of therapeutic candidates. Proposed are micro-physiological systems using human iPSC as a format for tissue-specific modeling of infection, the use of gene-humanized zebrafish and C. elegans for combinatorial drug screens due to the animals being addressable in liquid multi-well formats, and the use of engineered pseudo-typing systems to safely model infection in the transgenic animals and engineered tissue systems.",

keywords = "ACE2, COVID-19, SARS-CoV, antiviral, combination therapy",

author = "Christopher Hopkins and Chidinma Onweni and Victoria Zambito and Fairweather, {De Lisa} and Kathryn McCormick and Hideki Ebihara and Tom Caulfield and Zhang, {Yu Shrike} and Freeman, {W. David}",

note = "Publisher Copyright: {\textcopyright} 2021 The Author(s)",

year = "2021",

month = may,

day = "14",

doi = "10.1016/j.jmb.2021.166945",

language = "English (US)",

volume = "433",

journal = "Journal of Molecular Biology",

issn = "0022-2836",

publisher = "Academic Press Inc.",

number = "10",

}

TY - JOUR

T1 - Platforms for Personalized Polytherapeutics Discovery in COVID-19

AU - Hopkins, Christopher

AU - Onweni, Chidinma

AU - Zambito, Victoria

AU - Fairweather, De Lisa

AU - McCormick, Kathryn

AU - Ebihara, Hideki

AU - Caulfield, Tom

AU - Zhang, Yu Shrike

AU - Freeman, W. David

PY - 2021/5/14

Y1 - 2021/5/14

N2 - The COVID-19 pandemic entered its third and most intense to date wave of infections in November 2020. This perspective article describes how combination therapies (polytherapeutics) are a needed focus for helping battle the severity of complications from SARS-CoV-2 infection. It outlines the types of systems that are needed for fast and efficient combinatorial assessment of therapeutic candidates. Proposed are micro-physiological systems using human iPSC as a format for tissue-specific modeling of infection, the use of gene-humanized zebrafish and C. elegans for combinatorial drug screens due to the animals being addressable in liquid multi-well formats, and the use of engineered pseudo-typing systems to safely model infection in the transgenic animals and engineered tissue systems.

AB - The COVID-19 pandemic entered its third and most intense to date wave of infections in November 2020. This perspective article describes how combination therapies (polytherapeutics) are a needed focus for helping battle the severity of complications from SARS-CoV-2 infection. It outlines the types of systems that are needed for fast and efficient combinatorial assessment of therapeutic candidates. Proposed are micro-physiological systems using human iPSC as a format for tissue-specific modeling of infection, the use of gene-humanized zebrafish and C. elegans for combinatorial drug screens due to the animals being addressable in liquid multi-well formats, and the use of engineered pseudo-typing systems to safely model infection in the transgenic animals and engineered tissue systems.

KW - ACE2

KW - COVID-19

KW - SARS-CoV

KW - antiviral

KW - combination therapy

UR - http://www.scopus.com/inward/record.url?scp=85103625431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85103625431&partnerID=8YFLogxK

U2 - 10.1016/j.jmb.2021.166945

DO - 10.1016/j.jmb.2021.166945

M3 - Review article

C2 - 33753053

AN - SCOPUS:85103625431

SN - 0022-2836

VL - 433

JO - Journal of Molecular Biology

JF - Journal of Molecular Biology

IS - 10

M1 - 166945

ER -

Platforms for Personalized Polytherapeutics Discovery in COVID-19

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this